Previous Close | 3.7900 |
Open | 3.8300 |
Bid | 4.3500 x 3100 |
Ask | 4.3600 x 4000 |
Day's Range | 3.6300 - 3.8301 |
52 Week Range | 3.6300 - 14.5500 |
Volume | |
Avg. Volume | 8,474,940 |
Market Cap | 983.384M |
Beta (5Y Monthly) | 1.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2100 |
Earnings Date | Apr 30, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.19 |
Subscribe to Yahoo Finance Plus to view Fair Value for PACB
In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads The Market On March 12, the Nasdaq Composite Index was […]
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological disorders, including challenging-to-sequence genes with tandem repeat expansions. The new long-read workflow can minimize iterative analysis using legacy technology, and reduce the time needed to identify disease-causing variants and ass